LDV/SOF
Phase 2Small molecule
GileadLDV/SOF is one of 303 small molecule programs targeting Liver Transplant. It is currently in Phase 2.
9
Indications
38
Total Trials
0
Active Trials
302
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
LDV/SOF
GileadPhase 2
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
Medrol
PfizerPreclinical
Dasabuvir
AbbViePreclinical
SOF/VEL
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Safety and Efficacy9 trials
Show 6 more trials
Efficacy and Safety8 trials
Show 5 more trials
Chronic Hepatitis4 trials
Treatment4 trials
HCV Infection3 trials
8 more indications
Liver Transplant3 trials
Immunodeficiency1 trial
Hepatitis C1 trial
Sickle Cell Disease1 trial
Kidney Transplant1 trial
Renal insufficiency1 trial
Cirrhosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LDV/SOF. EMBL-EBI & Wellcome Sanger Institute.
- [4]